Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | HTR7 | P34969 | 1/20 | 0.43 |
| ▸ | HTR1B | P28222 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | HRH1 | P35367 | 1/20 | 0.40 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.40 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.40 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL73787 | 0.84 | CYP2C9 (0.41) | KDM4E | |
| SCHEMBL5585608 | 0.82 | ADRB2 (0.48) | KDM4EHTR7HTR1BALDH1A1SMN1; SMN2 | |
| SCHEMBL5585616 | 0.81 | KDM4E (0.47) | KDM4EHTR7HTR1BALDH1A1SMN1; SMN2 | |
| SCHEMBL13696631 | 0.81 | LOX (0.41) | KDM4EHTR1BALDH1A1HRH1 | |
| SCHEMBL5586046 | 0.80 | KDM4E (0.52) | KDM4EHTR7HTR1BALDH1A1SMN1; SMN2 | |
| SCHEMBL238407 | 0.77 | HTR7 (0.53) | KDM4EHTR7HTR1BALDH1A1SMN1; SMN2 | |
| SCHEMBL21730199 | 0.73 | LOX (0.45) | KDM4EALDH1A1HSD17B10ADRB2 | |
| SCHEMBL30880777 | 0.73 | LOX (0.45) | KDM4EALDH1A1HSD17B10ADRB2 | |
| SCHEMBL5585586 | 0.73 | HTR7 (0.69) | KDM4EHTR7HTR1BALDH1A1SMN1; SMN2 | |
| SCHEMBL21730330 | 0.73 | HTR7 (0.50) | KDM4EHTR7HTR1BALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7226925-B2 | Compounds, their use and preparation | BIOVITRUM AB (SE) | 2007-06-05 | — | — | US | disclosed |
| EP-1513831-A1 | NOVEL COMPOUNDS, THEIR USE AND PREPARATION | Biovitrum AB (SE) | 2005-03-16 | — | — | EP | disclosed |
| US-20040029888-A1 | Novel compounds, their use and preparation | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2004-02-12 | — | — | US | disclosed |
| WO-2004000830-A1 | NOVEL COMPOUNDS, THEIR USE AND PREPARATION | BIOVITRUM AB (SE) | 2003-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040029888-A1 | Novel compounds, their use and preparation | TPH1, TPH2, HTR1A | KDM4E 3125/4885HTR7 15/4885HTR1B 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.